普瑞巴林联用卡马西平治疗带状疱疹后神经痛的临床疗效及安全性研究

发布时间：2018-01-24 12:24

本文关键词： 带状疱疹后神经痛普瑞巴林卡马西平疗效安全性　出处：《医学理论与实践》2016年24期 　论文类型：期刊论文

【摘要】：目的:探讨普瑞巴林联合卡马西平治疗带状疱疹后神经痛(PHN)的疗效与安全性。方法:2012年2月-2014年8月收治PHN患者114例为研究对象,并根据患者用药情况分为卡马西平组(A组,n=39)、普瑞巴林组(B组,n=35)和普瑞巴林联用卡马西平组(C组,n=40),对比三组患者治疗前、后临床疗效及不良反应发生率有无差别。结果:治疗后三组患者VAS评分均明显降低(P0.05),C组治疗后各时点明显低于A组和B组,且差异有统计学意义(P0.05);治疗后三组患者睡眠持续时间均明显延长(P0.05),C组治疗后各时点持续睡眠时间优于A组和B组,且差异有统计学意义(P0.05);服药期间,C组眩晕、共济失调发生率显著低于A组(P0.05),与B组比较无明显差异(P0.05);但三组患者恶心呕吐、嗜睡和皮疹发生率差异无统计学意义(P0.05)。结论:普瑞巴林联用卡马西平治疗PHN疗效确切,能更好的缓解患者疼痛、提高患者睡眠质量的同时降低不良反应发生率。
[Abstract]:Objective: to investigate the effect of PreBahrain combined with carbamazepine in the treatment of postherpetic neuralgia (PHN). Methods: from February 2012 to August 2014, 114 patients with PHN were treated. The patients were divided into three groups according to their medication status: group A (carmazepine), group B (group B), group B (group B) and group C (group C) combined with carbamazepine (group C). Results: after treatment, the VAS scores of the three groups were significantly lower than that of the control group (P 0.05). Group C was significantly lower than group A and group B at each time point after treatment, and the difference was statistically significant (P 0.05). After treatment, the sleep duration of the three groups was significantly longer than that of group A and group B, and the difference was statistically significant (P 0.05). The incidence of vertigo and ataxia in group C was significantly lower than that in group A (P 0.05), but there was no significant difference between group B and group B (P 0.05). However, there was no significant difference in the incidence of nausea and vomiting, lethargy and rash among the three groups. Conclusion: prazin combined with carbamazepine is effective in the treatment of PHN and can relieve pain better. Improve the quality of sleep and reduce the incidence of adverse reactions.
【作者单位】：福建省莆田市第一医院神经内科;
【分类号】：R752.12
【正文快照】： 带状疱疹后神经痛(Post Herpetic Neuralgia,PHN)临床常见,病程长,常因顽固性疼痛影响患者生活质量[1]。卡马西平作为经典的抗癫痫药物被广泛用于该病的治疗,但仍有相当多的患者疼痛不能缓解。近年来普瑞巴林作为新型抗癫痫药在我国上市后被批准应用于治疗PHN。笔者于2012年12

【相似文献】